Cancer Treatment Reviews
Volume 35, Issue 7 , Pages 563-569 , November 2009

First-line chemotherapy of non-seminomatous germ cell tumors(NSGCTs)

Received 28 February 2009 ,Revised 18 May 2009 ,Accepted 19 May 2009.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66
  2. Korkola JE, Houldsworth J, Chavalavada RSV, et al. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res 2006;66(2):820–27.
  3. Sakuma Y, Sakurai S, Oguni S, et al. Alteration of the c-kit gene in testicular germ cell tumors. Cancer Sci. 2003;94(6):486–491
  4. Einhorm LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977;87(3):293–298
  5. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. New Engl J Med. 1987;316(23):1435–1440
  6. International Germ Cell Collaborative Group. Internation Gern Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15(2):594–603.
  7. O’Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14(1):91–96
  8. Berger CC, Bokemeyer C, Schneider M, et al. Secondary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer. 1995;31A(13–14):2229–2238
  9. Daugaard G, Nielsen H, Brunn B, et al. Infections in patients treated with high-dose chemotherapy for germ cell tumors. Eur J Cancer. 1993;29A(16):2220–2222
  10. Travis LB, Anderson M, Gospodarowicz M, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst. 2000;92(14):1165–1171
  11. Bokemeyer C, Berger CC, Kuczyk MA, et al. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol. 1996;14(11):2923–2932
  12. Doll DC, List AF, Greco FA, et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105(1):48–51
  13. Brydoy M, Fossa SD, Klepp O, et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst. 2005;97(21):1580–1588
  14. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol. 1989;7(3):387–391
  15. De Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001;19(6):1629–1640
  16. Toner GC, Stockler MR, Boyer MJ, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumors: a randomized trial. Australian and New Zealand Germ Cell Trial Group. Lancet 2001;357(9258):739–45.
  17. Levi JA, Raghavan D, Harvery D, et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol 1993;11(7):1300–05.
  18. Loehrer PJ, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995;13(2):470–476
  19. De Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997;15(5):1837–1843
  20. Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide+cisplatin versus vinblastine+bleomycin+cisplatin+cyclophosphamide+dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol. 1988;6(8):1231–1238
  21. Xiao H, Mazumbar M, Bajorin DF, et al. Long-term follow-up of patients with good risk germ-cell tumors treated with etoposide and cisplatin. J Clin Oncol. 1997;15:2553–2558
  22. Culine S, Kerbrat P, Kramar A, et al. Genito-Urinary Group of the French Federation of Cancer Center (GETUG T93BP). Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 2007;18(5):917–24.
  23. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ-cell tumors: a multiinstitutional study. J Clin Oncol. 1993;11(4):598–606
  24. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol. 1997;15(5):1844–1852
  25. Ozols RF, Ihde DC, Linehan WM, et al. A randomized trial of standard chemotherapy versus a high-dose chemotherapy regimen in the treatment of poor prognosis non-seminomatous germ-cell tumors. J Clin Oncol. 1988;6(6):1031–1040
  26. Nichols CR, Williams SD, Loehrer P, et al. Randomized study of cisplatin dose-intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol. 1991;9(7):1163–1172
  27. De Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP versus an alternating regimen of PVB and BEP in patients with poor-prognosis metastatic non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer. 1995;71(6):1311–1314
  28. Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic non-seminomatous tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol. 1998;16(2):692–701
  29. Germa-Lluch R, Garcia del Muro X, Tabernero JM, et al. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). Ann Oncol. 1999;10(3):289–293
  30. Logothetis CJ, Samuels ML, Selig DE, et al. Cyclic chemotherapy with cyclophosphamide, doxorubicine and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. Am J Med 1986;81(2):219–28.
  31. Blanke C, Loehrer PJ, Nichols CR, et al. A phase II trial of etoposide, ifosfamide, cisplatin, vinblastine and bleomycin in advanced germ-cell tumors. Am J Clin Oncol. 1996;19(5):487–491
  32. Bower M, Newlands ES, Holden L, et al. Treatment of men with metastatic non-seminomatous germ cell tumors with cyclical POMB/ACE chemotherapy. Ann Oncol. 1997;8:477–483
  33. Christian JA, Huddart RA, Norman A, et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol. 2003;21:871–877
  34. Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group and Cancer and Leukemia Group B study. J Clin Oncol. 1998;16(4):1287–1293
  35. De Wit R, Louwerens M, De Mulder PH, et al. Management of intermediate-prognosis germ cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer. 1999;83:831–833
  36. Mardiak J, Salek T, Sycova-Mila Z, et al. Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study. Neoplasma. 2007;54(3):240–245
  37. Pectasides D, Pectasides E, Papaxoinis G, et al. Methotrexate, paclitaxel, ifosfamide and cisplatin in poor-risk nonseminomatous germ cell tumors. Urol Oncol. 2008;24:1–6
  38. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25(3):247–256
  39. Droz JP, Kramar A, Biron P, et al. Genito-Urinary Group of the French Federation of Cancer Centers (GETUG). Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumors: mature results of a randomized trial. Eur Urol 2007;51(3):739–46.
  40. Hartmann JT, Gauler T, Metzner B, et al. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J Clin Oncol. 2007;25(36):5742–5747

PII: S0305-7372(09)00086-3

doi: 10.1016/j.ctrv.2009.05.004

Cancer Treatment Reviews
Volume 35, Issue 7 , Pages 563-569 , November 2009

Article Tools